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Abstract A specific immunoassay method with the colloidal
gold labeling technique has been developed more and more
for tuberculosis (TB) diagnosis. The aim of this multicenter
clinical evaluation was to evaluate the performance of a new
serological diagnostic kit (the Trustline TB IgG/IgM Rapid
Test kit) for the detection of Mycobacterium tuberculosis
infection in China, with the Aupu TB Ab (IgG) Colloidal
Gold Test kit being used as a control. A total of 1,009 spec-
imens were collected from three TB hospitals, including 628
patients with TB, and 219 non-TB and 162 healthy patients as
negative controls. According to the clinical diagnostic results,
the sensitivities of the Trustline kit and the Aupu kit were
61.3% and 53.7%, respectively. Using the bacteriological test
results as the “gold standard” to compare the results of the two
kits, the sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and Youden index
(YI) were 77.60 %, 79.8 %, 73.31 %, 81.50 %, and 0.574 by
the Trustline kit, and 67.86 %, 88.9 %, 83.27 %, 77.40 %, and
0.568 by the Aupu kit, respectively. Further, the sensitivity of
the Trustline kit and the Aupu kit for the smear staining and
the bacterial culture being positive was 75.6 %, 76.6 % and
65.6 %, 66.5 %, and for the negative result, it was 53.8 %,
50.9 % and 47.5 %, 45.0 %, respectively. Additionally, 35
specimens were IgM-positive by the Trustline kit; of these, 30
(4.8 %) were from patients with TB and 5 (1.3 %) were from
individuals without TB. The results showed that the experi-
mental test had a much higher sensitivity than the other
commercial test and exhibited a good detection rate for
M. tuberculosis infection. Therefore, this kit can be used in
the supplementary diagnosis and screening of TB.
Introduction
It is reported that tuberculosis (TB) caused byMycobacterium
tuberculosis (M. tuberculosis) infection has become one of the
major fatal infectious diseases among adults in the world [1].
China is one of the 22 countries in the world having a high TB
burden and has the second highest number of active TB cases,
with more than 1 million new cases of TB diagnosed each
year.
Currently, patients are diagnosed with TB based mainly on
clinical symptoms, X-rays, and conventional laboratory tests,
such as bacterial cultures and sputum smear acid-fast staining,
which exhibit much lower sensitivity. Acid-fast staining can-
not be used for the diagnosis of extrapulmonary TB, such as
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tuberculous pleurisy, tuberculosis of lymph nodes, tuberculosis
meningitis, etc., and bacterial culture is a time-consuming meth-
od that is unsuitable for rapid and early diagnosis, and it also has
very low sensitivity. Therefore, researchers are interested in the
development of new rapid-detection approaches, such as immu-
nological [2] and nucleic acid [3] detection techniques.
Since the 1980s, a number of new immunoassay tech-
niques has been developed using three labeling techniques
(fluorescein, radioisotopes, and enzymes) [4]. Such methods
were initially used only for immunoelectron microscopy;
however, over time, these methods have been used for addi-
tional applications in passive agglutination tests, light micros-
copy staining, immunoblotting, immunoblot filtration assays,
and immunoassays [5–7]. These techniques use chromatogra-
phy membranes precoated with specific substrate(s) as the
solid phase; as the sample solution moves through the mem-
brane by means of capillary action, the analytes in the sample
react with specific substrates with high affinity. The resulting
immune complexes are enriched or trapped within the mem-
brane and can be visualized with markers, such as colloidal
gold. This technology does not require special equipment, the
products have a long shelf life and can be stored at room
temperature, the operators do not need special training, and
results can be obtained within 10–20 min and observed by the
naked eye, making the immune colloidal gold technique es-
pecially suitable for the majority of rural and community
clinics and local hospitals, on-scene investigators, large-scale
urgent testing, and general disease surveys [4, 8–12].
In this clinical trial, we evaluated the performance of the
Trustline kit (produced by Beijing Genesee Biotech, Inc.)
against the Aupu kit, a dot immunogold filtration assay
(DIGFA) [13]. The Trustline kit, which can detect
M. tuberculosis IgG/IgM antibodies, uses a colloidal gold
immunochromatography method. It uses four recombinant
M. tuberculosis protein antigens (6, 14, 16, and 38 kDa)
simultaneously in a single-step procedure that is simple to
carry out and provides rapid results.
Materials and methods
This research was approved by the Ethics Committee of the
National Institute for Communicable Disease Control and Pre-
vention, Chinese Center for Disease Control and Prevention,
Beijing, China. All the patients included in this study provided
signed informed consent to participate in the investigation.
In this study, the experimental kit was the Trustline TB
IgG/IgM Rapid Test kit (Beijing Genesee Biotech, Inc., Bei-
jing, China). The control kit was an M. tuberculosis IgG
antibody colloidal gold kit, the Aupu TB Ab (IgG) Colloidal
Gold Test kit (Shanghai Aupu Biotechnology Co., Shanghai,
China), which had been approved by the China Food and
Drug Administration (CFDA, authorization code 20030090).
A total of 1,009 participants’ serum samples were collected
from three hospitals (Table 1), among which 628 TB samples
formed the case group, including 539 pulmonary TB and 89
Table 1 Distribution of serum
samples in the three different
hospitals in China
Samples Samples, n (%) Total, n
TB Non-TB Healthy
Beijing Geriatric Hospital (Beijing) 241 (72.8) 36 (10.9) 54 (16.3) 331
General Hospital of Huabei Oil Field Company 188 (53.7) 105 (30.0) 57 (16.3) 350
Cangzhou Infectious Disease Hospital (Hebei Province) 199 (60.7) 78 (23.8) 51 (15.5) 328
Total 628 (62.2) 219 (21.7) 162 (16.1) 1,009
Table 2 Demographic information for the 1,009 participants
Pulmonary TB (%) Extrapulmonary TB (%) Non-TB (%) Healthy Total
Total 539 (63.4) 89 (8.8) 219 (21.7) 162 (16.1) 1,009
Gender Male 351 (60.2) 56 (9.6) 140 (24.0) 86 (14.8) 583
Female 188 (50.0) 33 (8.8) 79 (21.0) 76 (20.2) 376
Age Mean±SD 45±1.83 38±1.78 39±2.08 35±1.67 43±1.96
≤14 7 (25.0) 3 (10.7) 6 (21.4) 12 (42.9) 28
>14 532 (54.2) 86 (8.8) 213 (21.7) 150 (15.3) 981
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extrapulmonary TB patients, and 381 samples comprised the
negative controls, including 162 medical examiners (healthy)
and 219 patients with non-TB lung diseases (non-TB). The
patients had an average age of 43±1.96 years, and the gender
ratio (male/female) was 1.69/1. The demographic information
for the 1,009 participants is shown in Table 2. All of the 1,009
participants were negative for human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS) diagnosed
with the China national diagnostic criteria and principles of
management of HIV/AIDS. The antibodies against HIV in hu-
man plasma was tested with a third-generation HIV antibody
enzyme-linked immunosorbent assay (ELISA) test, Vironostika
HIV-1/2 Microelisa System (bioMérieux, Holland), within 24 h,
according to the manufacturer’s instructions [14].
Diagnoses of pulmonary TB in the study were made with the
Clinical Diagnosis Standard of TB for Clinical Technology
Operation (TB volumes) of the Chinese Medical Association
published by the People’s Medical Publishing House (PMPH;
ISBN 9787117065108). Diagnoses of extrapulmonary TB were
made with the Guideline of the Ministry of Health of China. In
this study, we judged the final diagnosis of all patients with
curative effects.
We used the two kits (Trustline andAupu) to detect antibodies
against M. tuberculosis in the sera samples in accordance with
the respective manufacturer’s instructions. We compared the kits
using the sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), Youden index (YI), and nega-
tive and positive bacteriology rates.
The bacteria from the pulmonary TB patients were detected
by means of sputum smear acid-fast staining and
Mycobacterium culture on Löwenstein–Jensen medium [15].
The data were analyzed using SPSS statistical software
(version 16.0, SPSS Inc., Chicago, IL, USA). We used
Cohen’s kappa (κ) equivalence test to assess the equivalence
of the two testing kits [15], and the κ-value was interpreted as
follows:≥0.75, good; <0.75 and≥0.4, moderate;<0.4, poor.
We used the Z-test on a series of samples to analyze whether
there were differences between the test kits. Differences with
p-values of less than 0.05 were considered to be significant.
Results
Comparison of the results of all samples tested with the two
kits
For clinical diagnostic TB cases, the sensitivity of the
Trustline kit (61.3 %, 385/628) was significant higher than
that of the Aupu kit (53.7 %, 337/628) (p<0.05) (Table 3).
Table 3 Detection results from
the 1,009 specimens using the
two kits
Groups Trustline kit, n (%) Aupu kit, n (%) Total
Positive Negative Positive Negative
TB 385 (61.3) 243 (38.7) 337 (53.7) 291 (46.3) 628
Non-TB 53 (24.2) 166 (75.8) 31 (14.2) 188 (85.8) 219
Healthy controls 24 (14.8) 138 (85.2) 11 (6.8) 151 (93.2) 162
Total 462 547 379 630 1,009
Table 4 Serum antibodies detection results from the 539 pulmonary tuberculosis (TB) cases using bacteriological methods and the two kits
Bacteriological methods Trustline (IgG and IgM), n (%) Trustline (IgG), n (%) Aupu (IgG), n (%) Total
Positive Negative Positive Negative Positive Negative
Smear staining
Positive 167 (75.6) 54 (24.4) 167 (75.6) 54 (24.4) 145 (65.6) 76 (34.4) 221
Negative 171 (53.8) 147 (46.2) 171 (53.8) 147 (46.2) 151 (47.5) 167 (52.5) 318
Bacterial culture
Positive 190 (76.6) 58 (23.4) 190 (76.6) 58 (23.4) 165 (66.5) 83 (33.5) 248
Negative 148 (50.9) 143 (49.1) 148 (50.9) 143 (49.1) 131 (45.0) 160 (55.0) 291
Total of smear+culture
Positive 239 (77.6) 69 (22.4) 239 (77.6) 69 (22.4) 209 (67.9) 99 (32.1) 308
Negative 99 (42.9) 132 (57.1) 96 (41.6) 135 (58.4) 87 (37.7) 144 (62.3) 231
The χ2 test was used to analyze the IgG antibody positive rate of the two kits compared with smear staining and bacterial culture, respectively, p<0.05
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Comparison of the results between the bacteriological
methods and the two kits
Among the 628 TB cases diagnosed clinically, of the 89
extrapulmonary TB patients, the sensitivities of the Trustline
kit and the Aupu kit were 52.8 % (47/89) and 46.1 % (42/89),
respectively, and of the 539 pulmonary TB patients, the sen-
sitivities of smear staining, bacterial culture, the Trustline kit,
and the Aupu kit were 41.0 %, 46.0 %, 62.7 %, and 54.9 %,
respectively (Table 4). The sensitivities of the Trustline kit and
the Aupu kit were significantly higher than that of the bacterial
methods (p<0.05). The sensitivity of the Trustline kit and the
Aupu kit for testing sera antibody IgG was 62.2 %. The
sensitivity of the Trustline kit was significantly higher than
that of the Aupu kit (p<0.05).
Comparison of the results from the two kits using
bacteriological tests as the “gold standard”
Using the bacteriological test results as the “gold standard” to
compare the results of the two kits, the sensitivity, specificity,
PPV, NPV, and YI were 77.60 %, 79.8%, 75.6%, 81.9%, and
0.574 by the Trustline kit, and 67.9 %, 88.9 %, 83.3 %,
77.4 %, and 0.568 by the Aupu kit, respectively (Table 5).
Statistical analysis of the IgG antibody detection results
from the two kits
Using the IgG results from the Aupu kit as a reference, the
positive coincidence rate of the IgG results from the Trustline
kit was 70.8 % (269/380), the negative coincidence rate was
70.4 % (443/629), and the total coincidence was 70.6 % (712/
1,009) (Table 6). The equivalence test results gave a Cohen’s
κ-value of 0.4, indicating moderate equivalence for IgG
antibodies.
Comparison of the IgG/IgM antibody detection results using
the Trustline kit at the three hospitals
We compared the serum IgG/IgM antibody results from the
Trustline kit from the three hospitals. The sensitivities were
61.8 %, 67.3 %, and 54.3 %; the specificities 61.1 %, 83.7 %,
and 87.3%; PPVs 81.0%, 86.5%, and 83.0 %; NPVs 37.4%,
62.4 %, and 62.1 %; and YIs 0.23, 0.51, and 0.42, respective-
ly, which were all within the acceptable ranges (Table 7).
Assessment of the IgM antibody detection results measured
by the Trustline kit
The results showed that, of the 381 non-TB samples, 5 cases
(1.3 %) were positive, while among the 628 TB samples, 30
cases (4.8 %) were positive. Of these 30 clinically diagnosed
patients who were IgM-positive, two had acute hematogenous
disseminated TB, 28 cases were secondary to TB, and 26
cases (87 %) were positive for both IgG and IgM (Table 8).
Discussion
Several reviews have provided performance evaluations of
serological tests for rapid TB diagnosis [16–18]. A compre-
hensive review was published by Steingart et al. [17], who
used a bivariate random effects meta-analysis to prespecify
subgroups in order to address heterogeneity. They also sum-
marized test performance by analyzing papers published from
January 1, 1990 to June 29, 2010 after searching multiple
databases. For anti-TB IgG, the pooled sensitivities were 76%
in smear-positive and 59% in smear-negative patients, and the
pooled specificities were 92 % and 91 %, respectively. Com-
pared with ELISAs (pooled sensitivity, 60 %; pooled speci-
ficity, 98 %), immunochromatographic tests yielded lower
pooled sensitivity (53 %) and comparable pooled specificity
Table 5 Comparison of the detection results by the two kits using the bacteriological test results as the “gold standard” for TB diagnosis
Kits Sensitivity Specificity PPV NPV YI
Trustline kit 77.6 % (239/308) 79.8 % (304/381) 75.6 % (239/316) 81.9 % (304/371) 0.574
Aupu kit 67.9 % (209/308) 88.9 % (339/381) 83.3 % (209/251) 77.4 % (339/438) 0.568
p-Value <0.05 <0.05 >0.05 >0.05
NPV, negative predictive value; PPV, positive predictive value; YI, Youden index
Table 6 Comparison of IgG results detected by the two kits
Trustline kit Total
Aupu kit Positive Negative
Positive 269 111 380
Negative 186 443 629
Total 455 554 1,009
The χ2 test was used to analyze the IgG antibody-positive rate of the
Trustline kit with respect to the Aupu kit: χ2 =18.94, p=0.000, p<0.05
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(98 %). In another study, Steingart et al. [18] used culture and
clinical diagnosis methods as the reference standards. For
pulmonary TB (eight test evaluations), commercial serological
tests showed modest performance [diagnostic odds ratio
(DOR)=7.30], with a pooled sensitivity of 88 % and a pooled
specificity of 50 %; for extrapulmonary TB (four test evalua-
tions), the pooled sensitivity was less than 50% and the pooled
specificity was 93 %. In our current study using 1,009 speci-
mens, according to the clinical diagnostic results, the pooled
sensitivities and specificities of the Trustline kit and the Aupu
kit were 61.3 %, 79.8 % and 53.7 %, 88.9 %, respectively
(p<0.05). After further analysis according to the results of
smear staining and bacterial culture methods, the pooled sen-
sitivities of the Trustline kit and the Aupu kit were 75.6 %,
65.6 % and 76.6 %, 66.5 %, repectively (Tables 4 and 5).
Analysis of the results of this clinical experiment gave a
κ-value of 0.4 for IgG detection, indicating that there was no
significant difference in the overall clinical diagnostic perfor-
mance of the two kits. However, further analysis showed that,
using the bacteriological test results as the “gold standard” for
TB diagnosis to compare the results of the two kits, both the
sensitivity and specificity differed between the two kits (both
p<0.05). The sensitivities of the Trustline kit and the Aupu kit
for smear staining and bacterial culture negative were 53.8 %,
50.9 % and 47.5 %, 45.0 % respectively.
China has a high rate of TB infection (up to 44.5 % of the
population) [1, 19], but only 5–10 % of those infected exhibit
symptoms of active TB, and most of the remaining patients have
latent infections [1, 20]. With the increased sensitivity of detec-
tion methods, the detection rate of latent infection will be in-
creased, resulting in an increase in the false-positive rate and a
decrease in specificity.
In the large number of clinical samples used in this study,
the sensitivity of the Trustline kit was significantly better than
that of the Aupu kit. In addition, the Trustline kit has the
advantages of simple operation and short detection time, and
can detect both anti-TB IgG and IgM antibodies simulta-
neously in human serum or plasma.
In summary, our data demonstrated that the Trustline TB
IgG/IgM Rapid Test kit was more sensitive than the Aupu TB
Ab (IgG) Colloidal Gold Test kit in the detection of TB
antibodies in serum specimens. The Trustline TB IgG/IgM
Rapid Test kit could detect both IgG and IgM in one test
procedure and should be helpful for improving the detection
rate of TB.
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Table 7 Comparison of the IgG/IgM antibody detection results using the Trustline kit at the three hospitals
Groups Beijing Geriatric Hospital Cangzhou Infectious Disease Hospital General Hospital of Huabei Oil Field Company Total
Positive Negative Positive Negative Positive Negative Positive Negative
TB 149 92 134 65 102 86 385 243
Controls 35 55 21 108 21 141 77 304
Total 184 147 155 173 123 227 462 547
Control: non-TB+healthy; the χ2 test was used to analyze the IgG/IgM antibody-positive rate tested with the Trustline kit. For the case group, χ2 =7.02,
p=0.030, p<0.05, and for the control group, χ2 =25.99, p=0.000, p<0.05
Table 8 IgM antibody detection results for the 1,009 cases tested using
the Trustline kit
Case group Trustline kit Total
Positive Negative
Case group 30 598 628
Control group 5 376 381
Total 35 974 1,009
The χ2 test was used to analyze the IgM antibody-positive rate between
the case and control groups, χ2 =8.50, p=0.004, p<0.05
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